Biosynth Limited

Carbosynth Limited, based in the UK, specializes in the production of complex chemicals and biochemicals, primarily serving the pharmaceutical and life sciences sectors with innovative products and solutions. Carbosynth Limited provides a range of high-quality biochemical products and services. Founded in 1966, the company has maintained its operations in the UK and has undergone changes to enhance its offerings. The current CEOs are Martina Diekmann and Urs Spitz.

In November 2021, KKR agreed to acquire a majority stake in Carbosynth Limited, completing the transaction in March 2022, which has positioned the firm to expand its operational capabilities significantly. Carbosynth specializes in supplying a comprehensive array of high-quality products tailored for the pharmaceutical, life sciences, and diagnostics sectors. Their offerings include complex chemicals, peptides, and biologics, such as IVD reagents, antibodies, enzymes, and bioconjugates, which cater to diverse applications in drug development and diagnostics. The company operates various production facilities in Switzerland, the UK, Slovakia, and China, ensuring swift service to its global clientele, including pharmaceutical firms and research institutions.

In 2023, Carbosynth Limited reported a revenue of USD 20. 27 mn, with an EBITDA of USD -3. 20 mn, reflecting its operational performance for the financial year. Carbosynth Limited plans to accelerate its geographic expansion and broaden its product offerings in the coming years.

The acquisition completed in March 2022 will enhance its capacity and market presence. Specific new products are under design, with targeted launches planned for the near future, leveraging the new resources from KKR's investment to further establish itself in existing and new markets.